Clinical Trials of Atrasentan in Hormone-Refractory Prostate Cancer

Clinical Prostate Cancer

Volumn 2, Issue 2, 2003, Pages 84-86

  Lee, David ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ATRASENTAN; COLLAGEN; DEOXYPYRIDINOLINE; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; PLACEBO;

ARTICLE; BONE METABOLISM; BONE REMODELING; CANCER GROWTH; CANCER PAIN; CLINICAL TRIAL; DRUG EFFICACY; DYSPNEA; EDEMA; HEADACHE; HORMONE REFRACTORY PROSTATE CANCER; HUMAN; INFECTION; METASTASIS; PROSTATE CANCER; QUALITY OF LIFE; RHINITIS;

EID: 0142021922     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1540-0352(11)70025-7     Document Type: Article

References (17)

1. Valdenaire O, Rohrbacher E, Mattei MG. Organization of the gene encoding the human endothelin-converting enzyme (ECE-1). J Biol Chem 1995; 270:29794-29798.
2. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995; 1:944-949.
3. Nelson JB, Chan-Tack K, Hedican SP, et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 1996; 56:663-668.
4. Pirtskhalaishvili G, Nelson JB. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate 2000; 44:77-87.
5. Gohji K, Kitazawa S, Tamada H, et al. Expression of endothelin receptor a associated with prostate cancer progression. J Urol 2001; 165:1033-1036.
6. Casey ML, Byrd W, MacDonald PC. Massive amounts of immunoreactive endothelin in human seminal fluid. J Clin Endocrinol Metab 1992; 74:223-225.
7. Bohm F, Pernow J, Lindstrom J, et al. ETA receptors mediate vasoconstriction, whereas ETB receptors clear endothelin-1 in the splanchnic and renal circulation of healthy men. Clin Sci (Lond) 2003; 104:143-151.
8. Nelson JB, Lee WH, Nguyen SH, et al. Methylation of the 5′ CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res 1997; 57:35-37.
9. Opgenorth TJ, Adler AL, Calzadilla SV, et al. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther 1996; 276:473-481.
10. Carducci MA. Clinical Data and Phase III Trials with Atrasentan in Hormone Refractory Prostate Cancer. Presented at the 3rd annual Prostate Cancer Congress in Bermuda, July 2003.
11. Carducci MA, Nelson JB, Padley RJ, et al. The Endothelin-A Receptor Antagonist Atrasentan (ABT-627) Delays Clinical Progression in Hormone Refractory Prostate Cancer: a Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. Proc Am Soc Clin Oncol 2001; 20:174a (Abstract #694).
12. Carducci MA, Nelson JB, Humerickhouse R, et al. Effects of atrasentan on progression and survival in men with hormone refractory prostate cancer: follow-up study M96-594. Proc Am Soc Clin Oncol 2002; 21:178a (Abstract #708).
13. Singh A, Padley RJ, Ashraf T, et al. The Selective Endothelin-A Receptor Antagonist Atrasentan Improves Quality of Life Adjusted Time to Progression (QATTP) in Hormone Refractory Prostate Cancer Patients. Proc Am Soc Clin Oncol 2001; 20:393a (Abstract #1567).
14. Nelson JB, Carducci MA, Padley RJ, et al. The Endothelin-A Receptor Antagonist Atrasentan (ABT-627) Reduces Skeletal Remodeling Activity in Men with Advanced, Hormone Refractory Prostate Cancer. Proc Am Soc Clin Oncol 2001; 20:4a (Abstract #12).
15. Abbott Laboratories. Hormone-Naive Prostate Cancer Atrasentan Phase II Clinical Trial. Available at: http://abbott.com/innovation/clinical_trials_hormonenaive.html. Accessed June 4, 2003.
16. Abbott Laboratories Provides Update on Phase III Atrasentan Clinical Trials in Men with Advanced Prostate Cancer [press release]. Abbott Laboratories: News and Media Center; February 10, 2003.
17. A Phase III, Randomised, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of 10mg Atrasentan in Men with Non-Metastatic, Hormone-Refractory Prostate Cancer. Available at: http://www.addenbrookesoncology.co.uk/pdf/Atrasentan_244.pdf. Accessed on June 4, 2003.